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Abstract Fukuyama-type congenital muscular dystrophy
(FCMD) is an autosomal recessive severe muscular dystrophy
in combination with cerebral cortical dysplasia. Previously, we
identified the gene responsible for FCMD, termed fukutin,
through positional cloning. In this study, we have sequenced
131 892 bp of genomic DNA in the region of the fukutin gene on
chromosome 9q31 and obtained its complete genomic structure.
The fukutin genomic sequence spans approximately 100 kb and is
organized into 10 exons (41^6067 bp) and nine introns (1841^
21 460 bp). Using these sequence data, we have identified three
novel fukutin mutations in FCMD patients. We have also located
a putative TATA box in the flanking 5P region and identified
numerous alternatively spliced fukutin mRNA transcripts.
Analysis of expressed sequence tag clusters within the region
revealed two novel genes upstream of the fukutin gene. These
data provide fundamental information to support detailed genetic
and functional analyses of the fukutin gene. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Fukuyama-type congenital muscular dystrophy (FCMD;
MIM 253800) is an autosomal recessive disorder characterized
by primary dystrophic changes in skeletal muscle associated
with brain malformation, principally cerebral and cerebellar
cortical dysplasia [1]. It is the second most common form of
muscular dystrophy and one of the most common autosomal
recessive diseases in the Japanese population. FCMD patients
manifest generalized muscle weakness and hypotonia from
early infancy, and most of them are incapable of standing
or walking. In addition, some have seizures and all are men-
tally retarded. The predominant brain anomalies are micro-
polygyria, pachygyria and agyria. Ophthalmologic ¢ndings
such as peripheral abnormalities of the retina or abnormal
eye movements are often observed in FCMD patients. The
course of the disease is slowly progressive and inexorable,
and the majority of patients die during their second decade
of life [1].
Through a positional cloning approach, we recently identi-
¢ed the gene responsible for FCMD, termed fukutin [2^7].
Most FCMD patients analyzed to date carry an ancestral
mutation, which arose as a consequence of the integration
of a 3 kb retrotransposon element into the 3P untranslated
region of the fukutin gene [7]. This ancestral FCMD mutation
is the ¢rst known example of a human disease generated by an
ancient retrotransposon insertion. In addition, two point mu-
tations [6] and four other mutations [8] have been identi¢ed in
rare FCMD alleles, while several other alleles show no muta-
tions within the coding region.
The predicted protein product of the fukutin gene is a novel
461 amino acid protein that contains a potential N-terminal
signal sequence. A fukutin fusion protein was shown to be
exported from transfected cells [6]. While these observations
suggest that fukutin may be an extracellular matrix compo-
nent, its molecular function is not yet known.
In this study, we have determined the complete genomic
sequence of fukutin3 and obtained precise information pertain-
ing to the organization and transcriptional regulation of fu-
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 0 8 8 - 9
*Corresponding author. Fax: (81)-6-6879 3389.
E-mail: toda@clgene.med.osaka-u.ac.jp
1 The nucleotide sequence data reported in this paper have been
submitted to the GenBank/EMBL/DDBJ nucleotide sequence data-
bases with the accession number AB038490.
2 These authors contributed equally to this manuscript.
Abbreviations: FCMD, Fukuyama-type congenital muscular dystro-
phy; SNP, single nucleotide polymorphism; EST, expressed sequence
tag; ORF, open reading frame; WWS, Walker^Warburg syndrome
3
Published as ancillary material in the web version.
FEBS 24539 25-1-01
FEBS 24539FEBS Letters 489 (2001) 192^196
kutin that will facilitate characterization of additional muta-
tions in FCMD patients.
2. Materials and methods
In the course of positional cloning of the fukutin gene, we con-
structed YAC and cosmid contigs encompassing the FCMD candidate
region [5]. In the present study, we probed Southern blots with the
fukutin cDNA sequence to select ¢ve overlapping cosmid clones, c2D-
1, cJ5, cB12, cH1 and cE6, which constitute an approximately 130 kb
contig covering the fukutin gene. Cosmid DNA was puri¢ed using
Qiagen plasmid puri¢cation kits (Qiagen) or by equilibrium centrifu-
gation in CsCl^ethidium bromide gradients. Cosmid DNA was soni-
cated for 0.2 s at 20 W in a UD-201 Sonicator (Tomy) on ice, then
separated on a 0.8% agarose gel. Cosmid DNA fragments in the range
of 2^5 kb were excised from the gel, puri¢ed by electro-elution,
treated with T4 DNA polymerase and ligated into the EcoRV-di-
gested pBluescript II vector. A shotgun-sequencing library was gen-
erated using XL1-Blue competent cells under chloramphenicol selec-
tion. More than 150 shotgun clones were sequenced using an
AmpliTaq FS Dye Termination cycle sequencing kit with ABI Prism
377XL DNA Sequencer. Nucleotide sequences were assembled using
the Phred/Phrap/Consed programs (http://www.phrap.org/). Gaps be-
tween the assembled segments were connected through further se-
quencing of linking subclones using primers designed from the end
sequences of assembled segments [9].
Mutation identi¢cation was performed by direct sequence analysis
using previously described primers and sequencing methods [8]. In
brief, we PCR ampli¢ed and sequenced genomic DNA from each
patient who showed heterozygosity for the 3 kb insertion mutation
by Southern hybridization.
Total RNA was isolated from lymphoblasts using TRIzol Reagent
(Gibco). mRNA of fetal brain, adult brain and skeletal muscle was
obtained from commercial sources (Clontech). RNA was reverse-tran-
scribed using random primers and Superscript II reverse transcriptase
(Gibco). Primers 1F and 3R were used to amplify cDNA of the cod-
ing region of the fukutin gene. Primer sequences have been reported
elsewhere [8].
Potential CpG islands were detected using GRAIL software (http://
compbio.ornl.gov/Grail-1.3/). Analysis of upstream untranscribed se-
quence was carried out using the TFSEARCH, TESS, TSSG and
NNPP programs (available at http://www.rwcp.or.jp/lab/pdappl/
papia.html, http://www.cbil.upenn.edu/tess/index.html, http://dot.
imgen.bcm.tmc.edu:9331/gene-¢nder/gf.html and http://www.fruit
£ynrg/seq_tools/promoter.html, respectively). Transcription start sites
were also determined experimentally using the oligo-capping method
[10]. The RepeatMasker program (http://ftp.genome.washingtonndu/
RM/RepeatMasker.html) was used to screen DNA sequences for in-
terspersed repeats known to exist in mammalian genomes, such as Alu
and LINE 1. The BLAST program was used to determine sequence
similarity with known genes and expressed sequence tag (EST) se-
quences using the non-redundant and dbEST compilations from Gen-
Bank, EMBL and DDBJ databases. Amino acid sequence similarity
searches were carried out using FASTA and BLAST programs with
non-redundant SwissProt and PIR databases.
3. Results
The entire genomic sequence of the fukutin gene was deter-
mined from ¢ve cosmid clones: c2D-1, cJ5, cB12, cH1 and
cE6 (Fig. 1A). The inserts of the individual cosmids were
39 857, 38 025, 35 175, 37 211 and 36 852 bp in size, respec-
tively. Sequence data showed that the ¢ve cosmid clones cov-
ered a genomic region 131 892 bp in length3.
The fukutin gene, distributed across approximately 100 kb,
is comprised of 10 exons ranging in size from 41 to 6067 bp
(Fig. 1B and Table 1). Exon 2 contains the upstream untrans-
lated region, the initiation codon and the putative signal pep-
tide. The introns in fukutin ranged in size from 1841 to 21 460
bp, and all had consensus AG/GT sequences at the exon^
intron boundaries. Five exons displayed codon phase 0, and
three codons were split at splice junctions.
Fig. 1. Structural organization of the fukutin gene. The scale shown
corresponds to the nucleotide sequence determined in this study.
The position of the closest microsatellite, D9S2170, is indicated. (A)
Cosmids sequenced covering a 131 kb region on chromosome 9q31
that contains the fukutin gene. (B) Organization of fukutin. Vertical
bars and a box represent individual exons (see Table 1). (C) The lo-
cations of repetitive elements (Alu and LINE 1) in the region are
shown, with those in the forward orientation above the lines and
those in the reverse orientation below the lines. (D) Human ESTs
identi¢ed in the region are also indicated. ESTs in the forward di-
rection are above the line and ESTs in the reverse direction are be-
low the line. Three clusters of ESTs were found. The number of
ESTs constructing each cluster is also shown. One cluster corre-
sponds to the 3P-region of the fukutin gene, another is likely to be a
pseudogene ortholog of the rat tulip 2 gene, and the third might
represent a gene encoding a novel tyrosine kinase.
Table 1
Exon^intron boundaries in the fukutin gene
Exon 3P splice junction Exon size (bp) 5P splice junction Intron size (bp) Intron phase
1 41 GTTGAGTGAG/gtaaggtacg 16 777 UTR
2 ttgttcacag/AAAACAAAAT 193 ATCAACAAAG/gtaattttat 21 460 0
3 gtcttcctag/AATGGAGCTG 60 CACACAGTGG/gtatgtagaa 4 488 0
4 tctcaaacag/CGTGCAGTTA 204 GAAGAATGAG/gtaagtgact 2 866 0
5 ttggttctag/GAAGGCTGGT 278 CTTTTGACAG/gtaagttcag 3 330 2
6 ttgttttcag/GCCAGAGTTA 133 ATTCTTTCAG/gttagagaca 7 328 0
7 atatctgtag/CAGTACCTTG 130 ACTTGTCTAG/gtaaaattct 2 551 1
8 ttctttttag/GATGGTATCG 134 ATTTGGGAAG/gtcagtaaca 1 841 0
9 ttccccatag/GTAGAAGACA 128 AAAAATTCAA/gtatgaatca 14 987 2
10 tttgctgcag/ATACCTGTTT 6067
Exon sequence is in uppercase letters and intron sequence in lowercase letters. The positions of introns between codons are indicated by phase
0, interruption after the ¢rst nucleotide by phase 1, and interruption after the second nucleotide by phase 2. UTR, untranslated region.
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In addition to the FCMD families examined previously [2^
8], we analyzed an additional 29 families for mutations in this
study. Probands were homozygous in 19 families, and the
remaining 10 were heterozygous for the 3 kb insertion muta-
tion. Of these, three carried the previously reported C250T
non-sense mutation in fukutin [7,8], and three others carried
novel mutations: C718T non-sense, T1169A non-sense and
A1223G missense mutations (Table 2). We identi¢ed a single
nucleotide polymorphism (SNP) at base position 719, either A
or G. The patient carrying the C718T transition was homo-
zygous for G at position 719; thus, the C718T transition
represents a non-sense mutation (CGA to TGA). To deter-
mine whether the A1223G substitution was a polymorphism
or a disease-causing mutation, we tested 50 normal individuals
for this change. We did not detect this change in any of the 50
controls (data not shown), indicating that the A1223G muta-
tion is probably disease-causing. The remaining four patients
who were heterozygous for the 3 kb insertion showed no
alterations in the coding or the exon^intron boundary regions.
For all compound heterozygous genotypes, patients’ pheno-
types were severe.
Examination of the £anking sequence 5P to the fukutin gene,
which included exon 1, revealed a relatively GC-rich sequence
containing the BssHII restriction site. A CpG island was pre-
dicted in this region by the GRAIL program (data not
shown). Moreover, a portion of this region was previously
cloned as a CpG island genomic fragment (Z57056) [11].
Therefore, the 5P £anking sequence is likely to form a CpG
island.
We analyzed a 360 bp sequence immediately upstream of
the 5P end of the fukutin cDNA for the presence of promoter
sequences using computer programs (TFSEARCH, TESS,
TSSG and NNPP). This sequence contained a number of
putative transcription elements, including a TATA box and
two potential transcription initiation sites (Fig. 2). Transcrip-
tion start sites were also determined using the oligo-capping
method with human colon mRNA [10], although the pre-
dicted start sites and the experimentally obtained sites were
di¡erent. The roles of putative regulatory elements and the
true sites of transcription initiation will require further evalu-
ation.
Sunada et al. (submitted for publication) found that fukutin
produced extensive alternative splicing products. Through
RT-PCR ampli¢cation with primers speci¢c for the fukutin
open reading frame (ORF), we also identi¢ed a single major
fukutin transcript along with multiple minor transcripts in this
study. Transcripts showed identical expression patterns in fe-
tal brain, adult brain, skeletal muscle and lymphoblast (Fig.
3A). Sequence analysis showed that the predominant tran-
script contained the entire fukutin coding region and that at
least 18 minor transcripts were produced by alternative splic-
ing (Fig. 3B). Most showed insertions of new exons and/or
deletions of original exons, predicting amino acid changes and
protein truncation. One lacked the initiating methionine co-
don of the fukutin gene and two had in-frame deletions.
We determined the copy number of repetitive sequences
within the 132 kb region using the RepeatMasker program.
This analysis revealed 39 copies of the Alu sequence (average
of one copy per 3.4 kb) and 26 copies of the partial or full-
length LINE 1 sequence (average of one copy per 5.1 kb) (Fig.
1C). A relatively high frequency of LINE 1 elements in this
region is consistent with the location of the fukutin gene on
the 9q31 G band. The interspersed repeats constitute as much
as 42.89% of the DNA in this region. While such repeat se-
quences are thought to be associated with mutations involving
gene deletion, no large deletions have been identi¢ed to date
in FCMD patients. D9S2170, a previously identi¢ed polymor-
phic (CA)n repeat critical for founder-haplotype mapping of
fukutin, is located distal to exon 10 (Fig. 1) [6].
Database searching using the genomic sequence revealed
three EST clusters within the region (Fig. 1D). One cluster,
consisting of 14 ESTs, corresponds to the 3P-region of the
fukutin gene. A second cluster of 37 ESTs (GenBank:
AI052024, AA115176, AA481144, etc.) shares extensive sim-
ilarity with the rat tulip 2 gene (GenBank: AF041107). How-
ever, the lack of both introns and continuous ORFs in the
genomic sequence, suggests that this is likely a processed pseu-
dogene. The third cluster, containing 30 ESTs (GenBank:
AI084495, AA195108, N98696, etc.), most likely represents a
gene encoding a novel tyrosine kinase. The putative transla-
tion of this sequence shares similarity with EPH-related re-
ceptor protein-tyrosine kinases (Swiss-Prot: P54753, P54760,
P54762).
Table 2
Summary of fukutin mutations and a SNP found in this study
Nucleotide change Coding e¡ect Amino acid change Age/sex Phenotype
Mutation:
C718T non-sense R203X 3 years 7 months/female severe
T1169A non-sense L353X 1 year 2 months/male severe
A1223G missense T371C 0 year 2 months/male severe
Polymorphism :
A719G non-synonymous Q203R
Fig. 2. Nucleotide sequences in the 5P-£anking region of the fukutin
gene. Exon 1 sequences reported previously are in boldface and in-
tron 1 sequences in lowercase letters. Nucleotides are numbered on
the right. Nucleotide position +1 is assigned to the ¢rst nucleotide
of exon 1, as reported previously. Transcription initiation sites ob-
tained by oligo-capping method are indicated by asterisks. The pu-
tative TATA box is underlined in boldface, and predicted sites for
the transcription initiation are indicated in boldface italics.
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4. Discussion
The present study describes the structural organization and
genomic sequencing of the fukutin gene3. These data represent
a necessary step in the development of a DNA-based muta-
tion screen for FCMD. This is particularly important for
FCMD because of the wide spectrum of clinical variability,
from relatively mild to severe. Walker^Warburg syndrome
(WWS) and muscle^eye^brain disease are well known congen-
ital muscular dystrophies that also involve central nervous
system abnormalities and ocular malformations [12^15].
Although both syndromes are generally more severe than
FCMD, it is sometimes di⁄cult to distinguish severe FCMD
from WWS clinically [16^18]. In a recent study, we used se-
quence data presented here to identify four novel mutations in
rare alleles. Moreover, we found that compound heterozy-
gotes for the founder mutation, including two patients with
WWS-like phenotype, were clinically more severe than pa-
tients homozygous for the founder mutation [8,18].
In the present study, we have identi¢ed three additional
novel mutations in compound heterozygous patients. These
patients showed severe clinical phenotypes, supporting our
previous observations. Thus, it may be possible to re-classify
muscular dystrophies based on genetic rather than clinical
criteria. Cataloguing deleterious mutations of the fukutin
gene in patients should also highlight functionally important
amino acid residues within fukutin protein, providing a basis
for structure^function analyses.
The Japanese mother of the patient carrying the T1169 non-
sense mutation carried the founder insertion chromosome,
Fig. 3. Schematic representation of extensive alternative splicing of the fukutin gene. (A) Multiple transcripts detected by RT-PCR. (B) The ma-
jor transcript is shown on the top. The black box represents the ORF of each transcript. The number of amino acids encoded is denoted on
the right.
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while the Chinese father carried the non-sense mutation. This
suggests that there may exist more patients or carriers in Asia
than previously thought, although FCMD seems to be very
rare in ethnic groups other than the Japanese population.
Several rare FCMD alleles show no mutation within the
coding region of the fukutin gene. It is probable that the
mutations in these alleles lie in regulatory regions such as
promoter sequences or intronic sequences critical for alterna-
tive splicing. The fukutin gene was observed in this study to
produce extensive alternative splicing transcripts : one major
transcript carrying the entire coding region of fukutin and at
least 18 minor transcripts. Although the biological signi¢cance
of the minor transcripts is unknown, it is possible that they
supplement the function of fukutin at the level of either
mRNA or protein. Alternatively, it is possible that the expres-
sion levels of some transcripts increase, owing to the mutation
in intronic sequences, and that the relative decrease of normal
fukutin contributes to the disease. We have identi¢ed one
FCMD-causative mutation resulting from the insertion of
the LINE 1 repetitive element into intron 7. This insertion
results in an increase of the amounts of minor transcripts
lacking exon 7, 8 and/or 9 relative to the major transcript
[8]. Using the genomic sequence of the fukutin gene, we are
now able to search for other such mutations, analyze the
regulation of fukutin expression and identify new genes within
the region.
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